A simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia.

Heini, Alexander D.; Hugo, Rebecca; Berger, Martin D.; Novak, Urban; Bacher, Ulrike; Pabst, Thomas (2020). A simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia. Hematological oncology, 38(1), pp. 74-81. Wiley 10.1002/hon.2696

[img]
Preview
Text
Heini et al 2019.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (898kB) | Preview

High levels of acute phase reactants can be associated with adverse outcome in patients with various solid tumor types. For patients with acute myeloid leukemia (AML), this correlation is unknown. We retrospectively investigated the prognostic value of pretreatment acute phase protein levels in 282 consecutive newly diagnosed AML patients undergoing at least one cycle of intensive induction chemotherapy. We applied a new score integrating pre-treatment C-reactive protein (CRP), fibrinogen, and albumin levels termed the CFA ratio, and we stratified patients into two groups: Patients with a CFA ratio below 3.06 had decisively better progression free (26.2 vs. 7.7 months; P<.001), disease free (56.4 vs. 8.7 months; P<.001) and overall survival (61.2 vs. 13.8 months; P<.001). Results remained significant when adjusting for confounders including ELN risk group. Early mortality also tended to be lower in the low CFA ratio group. Finally, patients with lower modified Glasgow prognostic score (mGPS) similarly had better outcome. In conclusion, our data suggest that an elevated CFA ratio as well as a high mGPS are associated with adverse outcome in patients with newly diagnosed AML undergoing intensive induction. These parameters should undergo prospective evaluation for their contribution to risk profiling in AML patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Heini, Alexander; Berger, Martin Dave; Novak, Urban; Bacher, Vera Ulrike and Pabst Müller, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1099-1069

Publisher:

Wiley

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

02 Dec 2019 16:21

Last Modified:

22 Nov 2020 02:30

Publisher DOI:

10.1002/hon.2696

PubMed ID:

31755141

Uncontrolled Keywords:

AML CRP acute phase protein albumin fibrinogen outcome prognosis

BORIS DOI:

10.7892/boris.135837

URI:

https://boris.unibe.ch/id/eprint/135837

Actions (login required)

Edit item Edit item
Provide Feedback